Dry eye: an inflammatory ocular disease

Michelle Hessen, Esen Karamursel Akpek, Michelle Hessen, Esen Karamursel Akpek

Abstract

Keratoconjunctivitis sicca, or dry eye, is a common ocular disease prompting millions of individuals to seek ophthalmological care. Regardless of the underlying etiology, dry eye has been shown to be associated with abnormalities in the pre-corneal tear film and subsequent inflammatory changes in the entire ocular surface including the adnexa, conjunctiva and cornea. Since the recognition of the role of inflammation in dry eye, a number of novel treatments have been investigated designed to inhibit various inflammatory pathways. Current medications that are used, including cyclosporine A, corticosteroids, tacrolimus, tetracycline derivatives and autologous serum, have been effective for management of dry eye and lead to measurable clinical improvement.

Keywords: Dry Eye; Inflammation; Keratoconjunctivitis Sicca; Sjӧgren’s Syndrome; Treatment.

References

    1. Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol. 2000;118:1264–1268.
    1. The definition and classification of dry eye disease: report of the definition and classification subcommittee of the international dry eye workshop (2007). Ocul Surf. 2007;5:75–92.
    1. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren syndrome: a revised version of the European criteria proposed by the American-European consensus group. Ann Rheum Dis. 2002;61:554–558.
    1. Shiboski SC, Shiboski CH, Criswell L, Baer A, Challacombe S, Lanfranchi H, et al. American College of Rheumatology Classification Criteria for Sjögren’s Syndrome: A Data-Driven, Expert Consensus Approach in the SICCA Cohort. Arthritis Care Res (Hoboken) 2012;64:475–487.
    1. Djalilian AR, Hamrah P, Pflugfelder SC. Dry eye. In: Krachmer JH, Mannis MJ, Holland EJ, editors. Cornea. 2nd ed. Philadelphia. Elsevier Mosby; 2005.
    1. Akpek EK, Klimava A, Thorne JE, Martin D, Lekhanont K, Ostrovsky A. Evaluation of patients with dry eye for the presence of underlying Sjögren syndrome. Cornea. 2009;28:493–497.
    1. Liew M, Zhang M, Kim E, Akpek EK. Prevalence and predictors of Sjogren’s syndrome in a prospective cohort of patients with aqueous deficient dry eye. Br J Ophthalmol. 2012;96:1498–1503.
    1. Gupta A, Sadeghi PB, Akpek EK. Occult thyroid eye disease in patients presenting with dry eye symptoms. Am J Ophthal. 2009;147:919–923.
    1. The epidemiology of dry eye disease: Report of the Epidemiology Subcommittee of the International Dry Eye Workshop. Ocul Surf. 2007;5:93–107.
    1. Connor CG, Flockencier LL, Hall CW. The influence of gender on the ocular surface. J Am Optom Assoc. 1999;70:182–186.
    1. Krenzer KL, Dana MR, Ullman MD, Cermak JM, Tolls DB, Evans JE, et al. Effect of androgen deficiency on the human meibomian gland and ocular surface. J Clin Endocrinol Metab. 2000;85:4874–4882.
    1. Schaumberg DA, Buring JE, Sullivan DA, Dana MR. Hormone replacement therapy and dry eye syndrome. JAMA. 2001;286:2114–2119.
    1. Ang RT, Dartt DA, Tsubota K. Dry eye after refractive surgery. Curr Opin Ophthalmol. 2001;12:318–322.
    1. Lee AJ, Lee J, Saw SM, Gazzard G, Koh D, Widjaja D, et al. Prevalence and risk factors associated with dry eye symptoms: a population based study in Indonesia. Br J Ophthalmol. 2002;86:1347–1351.
    1. Schlote T, Kadner G, Frudenthaler N. Marked reduction and distinct pattern of eye blinking in patients with moderately dry eyes during video display terminal use. Graefes Arch Clin Exp Ophthalmol. 2004;242:306–312.
    1. Wolkoff P, Nøjaard JK, Franck C, Skov P. The modern office environments desiccate the eye? Indoor Air. 2006;16:258–265.
    1. Management and therapy of dry eye disease: Report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop. Ocul Surf. 2007;5:163–178.
    1. Kunert KS, Tisdale AS, Stern ME, Smith JA, Gipson IK. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol. 2000;118:1489–1496.
    1. Stern ME, Gao J, Schwalb TA, Ngo M, Tieu DD, Chan CC, et al. Conjunctival T-cell subpopulations in Sjögren’s and non-Sjögren’s patients with dry eye. Invest Ophthalmol Vis Sci. 2002;43:2609–2614.
    1. Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder SC. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci. 2001;42:2283–2292.
    1. Cejková J, Ardan T, Simonová Z, Cejka C, Malec J, Jirsová K, et al. Nitric oxide synthase induction and cytotoxic nitrogen-related oxidant formation in conjunctival epithelium of dry eye (Sjögren’s syndrome). Nitric Oxide. 2007;17:10–17.
    1. Paul A, Wilson S, Belham CM, Robinson CJ, Scott PH, Gould GW, et al. Stress-activated protein kinases: activation, regulation and function. Cell Signal. 1997;9:403–410.
    1. Pflugfelder SC, de Paiva CS, Tong L, Luo L, Stern ME, Li DQ. Stress-activated protein kinase signaling pathways in dry eye and ocular surface disease. Ocul Surf. 2005;3(Suppl 4):154–157.
    1. Luo L, Li DQ, Doshi A, Farley W, Corrales RM, Pflugfelder SC. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis Sci. 2004;45:4293–4301.
    1. Li DQ, Luo L, Chen Z, Kim HS, Song XJ, Pflugfelder SC. JNK and ERK MAP kinases mediate induction of IL-1beta, TNF-alpha and IL-8 following hyperosmolar stress in human limbal epithelial cells. Exp Eye Res. 2006;82:588–596.
    1. Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology. 2000;47:119–125.
    1. Stevenson W, Chauhan SK, Dana R. Dry Eye Disease: an immune-mediated ocular surface disorder. Arch Ophthalmology. 2012;130:90–100.
    1. Pflugfelder SC, Wilhelmus KR, Osato MS, Matoba AY, Font RL. The auto-immune nature of aqueous tear deficiency. Ophthalmology. 1986;93:1513–1517.
    1. Stern ME, Gao J, Siemasko KF, Beuerman RW, Pflugfelder SC. The role of the lacrimal gland functional unit in the pathophysiology of dry eye. Exp Eye Res. 2004;78:409–416.
    1. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporine A ophthalmic emulsion in the treatment of moderate to severe dry eye disease: a dose-ranging, randomized trial. The Cyclospoine A Phase 2 Study Group. Ophthalmology. 2000;107:967–974.
    1. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 2000;107:631–639.
    1. Laibovitz RA, Solch S, Andriano K, O'Connell M, Silverman MH. Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca. Cornea. 1993;12:315–323.
    1. Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol. 2002;120:330–337.
    1. Utine CA, Stern M, Akpek EK. Clinical review: topical ophthalmic use of cyclosporin A. Ocul Immunol Inflamm. 2010;18:352–361.
    1. Dastjerdi MH, Hamrah P, Dana R. High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen. Cornea. 2009;28:1091–1096.
    1. Thomson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit. 1995;17:584–591.
    1. Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, et al. FK-506, a novel immunosuppressant isolated from Streptomyces. I. Fermentation isolation, and physio-chemical and biological characteristics. J Antibiot (Tokyo) 1987;40:1249–1255.
    1. Attas-Fox L, Barkana Y, Iskhakov V, Rayvich S, Gerber Y, Morad Y, et al. Topical tacrolimus 0.03% ointment for intractable allergic conjunctivitis: an open-label pilot study. Curr Eye Res. 2008;33:545–549.
    1. Bertelmann E, Pleyer U. Immunomodulatory therapy in ophthalmology-is there a place for topical application? Ophthalmologica. 2004;218:359–367.
    1. Fei WL, Chen JQ, Yuan J, Quan DP, Zhou SY. Preliminary study of the effect of FK506 nanospheric-suspension eye drops on rejection of penetrating keratoplasty. J Ocul Pharmacol Ther. 2008;24:235–244.
    1. Fujita E, Teramura Y, Mitsugi K, Ninomiya S, Iwatsubo T, Kawamura A, et al. Absorption, distribution, and excretion of 14C-labeled tacrolimus (FK506) after a single or repeated ocular instillation in rabbits. J Ocul Pharmacol Ther. 2008;24:333–343.
    1. Fujita E, Teramura Y, Shiraga T, Yoshioka S, Iwatsubo T, Kawamura A, et al. Pharmacokinetics and tissue distribution of tacrolimus (FK506) after a single or repeated ocular instillation in rabbits. J Ocul Pharmacol Ther. 2008;24:309–319.
    1. Nishino K, Fukushima A, Okamoto S, Ohashi Y, Fukata K, Ozaki A, et al. Suppression of experimental immune-mediated blepharoconjunctivitis in Brown Norway rats by topical application of FK506. Graefes Arch Clin Exp Ophthalmol. 2002;240:137–143.
    1. Pleyer U, Lutz S, Jusko WJ, Nguyen KD, Narawane M, Rückert D, et al. Ocular absorption of topically applied FK506 from liposomal and oil formulations in the rabbit eye. Invest Ophthalmol Vis Sci. 1993;34:2737–2742.
    1. Sasakawa Y, Sakuma S, Higashi Y, Sasakawa T, Amaya T, Goto T. FK506 suppresses neutrophil chemoattractant production by peripheral blood mononuclear cells. Eur J Pharmacol. 2000;403:281–288.
    1. Reitamo S, Van Leent EJ, Ho V, Harper J, Ruzicka T, Kalimo K, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol. 2002;109:539–546.
    1. Reitamo S, Rustin M, Ruzicka T, Cambazard F, Kalimo K, Friedmann PS, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol. 2002;109:547–555.
    1. Reitamo S, Remitz A, Kyllönen H, Saarikko J. Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis. Am J Clin Dermatol. 2002;3:381–388.
    1. Aoki S, Mizote H, Minamoto A, Suzuki M, Mishima HK, Tanaka H. Systemic FK506 improved tear secretion in dry eye associated with chronic graft versus host disease. Br J Ophthalmol. 2005;89:243–244.
    1. Ryu EH, Kim JM, Laddha PM, Chung ES, Chung TY. Therapeutic effect of 0.03% tacrolimus for ocular graft versus host disease and vernal keratoconjunctivits. Korean J Ophthalmol. 2012;26:241–247.
    1. Tam PM, Young AL, Cheng AL, Lam PT. Topical 0.03% tacrolimus ointment in the management of ocular surface inflammation in chronic GVHD. Bone Marrow Transplant. 2010;45:957–958.
    1. Moscovici BK, Holzchuh R, Chiacchio BB, Santo RM, Shimazaki J, Hida RY. Clinical treatment of dry eye using 0.03% tacrolimus eye drops. Cornea. 2012;31:945–949.
    1. Comstock T, DeCory H. Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate. Int J Inflam. 2012;2012:789623.
    1. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids - new mechanisms for old drugs. N Engl J Med. 2005;353:1711–1658.
    1. Newton R. Molecular mechanisms of glucocorticoid action: what is important? Thorax. 2000;55:603–613.
    1. Stahn C, Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol. 2008;4:525–533.
    1. Marsh P, Pflugfelder SC. Topical nonpreserved methylpresdnisolone therapy of keratoconjunctivits sicca in sjogren’s syndrome. Ophthalmology. 1999;106:811–816.
    1. Pflugfelder SC, Maskin SL, Anderson B, Chodosh J, Holland EJ, De Paiva CS, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004;138:444–457.
    1. McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf. 2002;25:33–55.
    1. Solomon A, Rosenblatt M, Li D, Monroy D, Ji Z, Lokeshwar BL, et al. Doxycycline inhibition of interleukin-1 in the cornea epithelium. Am J Ophthalmol. 2000;130:688.
    1. De Paiva CS, Corrales RM, Villarreal AL, Farley WJ, Li DQ, Stern ME, et al. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Exp Eye Res. 2006;83:526–535.
    1. De Paiva CS, Corrales RM, Villarreal AL, Farley W, Li DQ, Stern ME, et al. Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylprednisolone and doxycycline. Invest Ophthalmol Vic Sci. 2006;47:2847–2856.
    1. Nikodemova M, Watters JJ, Jackson SJ, Yang SK, Duncan ID. Minocycline downregulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC) alpha/betaII. J Biol Chem. 2007;282:15208–15216.
    1. Frucht-Pery J, Sagi E, Hemo I, Ever-Hadani P. Efficacy of doxycycline and tetracycline in ocular rosacea. Am J Ophthalmol. 1993;116:88–92.
    1. Zengin N, Tol H, Gündüz K, Okudan S, Balevi S, Endoğru H. Meibomian gland dysfunction and tear film abnormalities in rosacea. Cornea. 1995;13:144–146.
    1. Akpek EK, Merchant A, Pinar V, Foster CS. Ocular rosacea: patient characteristics and follow-up. Ophthalmology. 1997;104:1863–1867.
    1. Dursun D, Kim MC, Solomon A, Pflugfelder SC. Treatment of recalcitrant corneal epithelial erosions with inhibitors of matrix metalloproteinases-9, doxycycline and corticosteroids. Am J Ophthalmol. 2001;132:8–13.
    1. Hope-Ross MW, Chell PB, Kervick GN, McDonnell PJ, Jones HS. Oral tetracycline in the treatment of recurrent corneal erosions. Eye (Lond) 1994;8:384–388.
    1. Liou LB. Serum and in vitro production of IL-1 receptor antagonist correlate with C-reactive protein levels in newly diagnosed, untreated lupus patietns. Clin Exp Rheumatol. 2001;19:515–523.
    1. Ji H, Pettit A, Ohmura K, Ortiz-Lopez A, Duchatelle V, Degott C, et al. Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J Exp Med. 2002;196:77–85.
    1. Paramo JA, Orbe J, Fernandez J. Fibrinolysis/proteolysis balance instable angina pectoris in relation to angiographic findings. Thromb Haemost. 2001;86:636–639.
    1. Fox RI, Chan R, Michelson JB, Belmont JB, Michelson PE. Beneficial effect on artificial tears made with autologous serum in patients with Keratoconjunctivitis sicca. Arthritis Rheum. 1984;27:459–61.
    1. Kono I, Kono K, Narushima K, Akama T, Suzuki H, Yamane K, et al. Beneficial effect of the local application of plasma fibronectin and autologous serum in patients with Keratoconjunctivitis sicca of Sjogren’s syndrome. Ryumachi. 1986;26:339–343.
    1. Tsubota K, Goto E, Fujita H, Ono M, Inoue H, Saito I, Shimmura S , et al. Treatment of dry eye by autologous serum application in Sjogren’s syndrome. Br J Ophthamol. 1999;83:390–395.
    1. Tananuvat N, Daniell M, Sullivan LJ, Yi Q, McKelvie P, McCarty DJ, et al. Controlled study of the use of autologous serum in dry eye patients. Cornea. 2001;20:802–806.
    1. Versura P, Profazio V, Buzzi M, Stancari A, Arpinati M, Malavolta N, et al. Efficacy in standardized and quality-controlled cord blood serum eye drop therapy in the healing of severe corneal epithelial damage in dry eye. Cornea. 2013;32:412–418.
    1. Yoon KC, Jeong IY, Im SK, et al. Therapeutic effect of umbilical cord serum for the treatment of dry eye associated with graft-versus-host disease. Bone Marrow Transplant. 2007;39:231–235.
    1. Na KS, Kim MS. Allogenic serum eye drops for the treatment of dry eye patients with chronic graft-versus-host disease. J Ocul Pharmacol Ther. 2012;28:479–483.
    1. Gabay C, Porter B, Fantuzzi G, Arend WP. Mouse IL-1 receptor antagonist isoforms: complementary DNA cloning and protein expression of intracellular isoform and tissue distribution of secreted and intracellular IL-1 receptor antagonist in vivo. J Immunol. 1997;159:5905–5913.
    1. Okanobo A, Chauhan SK, Dastjerdi MH, Kodati S, Dana R. Efficacy of topical blockade of interleukin-1 in experimental dry eye disease. Am J Ophthalmol. 2012;154:63–71.
    1. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol. 2008;8:349–361.
    1. Li N, He J, Schwartz CE, Gjorstrup P, Bazan HE. Resolvin E1 improves tear production and decreases inflammation in a dry eye mouse model. J Ocul Pharmacol Ther. 2010;26:431–439.
    1. de Paiva CS, Schwartz CE, Gjörstrup P, Pflugfelder SC. Resolvin E1 (RX-10001) reduces corneal epithelial barrier disruption and protects against goblet cell loss in a murine model of dry eye. Cornea. 2012;31:1299–1303.
    1. Cortina MS, Bazan HE. Docosahexaenoic acid, protectins and dry eye. Curr Opin Clin Nutr Metab Care. 2011;14:132–137.
    1. Tylaska LA, Boring L, Weng W, Aiello R, Charo IF, Rollins BJ, et al. CCR2 regulates the level of MCP-1/CCL2 in vitro and at inflammatory sites and controls T cell activation in response to alloantigen. Cytokine. 2002;18:184–190.
    1. Oshima T, Sonoda KH, Tsutsumi-Miyahara C, Qiao H, Hisatomi T, Nakao S, et al. Analysis of corneal inflammation induced by cauterisation in CCR2 and MCP-1 knockout mice. Br J Ophthalmol. 2006;90:218–222.
    1. Goyal S, Chauhan S, Zhang Q, Dana R. Amelioration of murine dry eye disease by topical antagonist to chemokine receptor 2. Arch Ophthalmol. 2009;127:882–887.
    1. Ghoreschi K, Laurence A, O’Shea JJ. Janus kinase in immune cell signaling. Immunol Rev. 2009;228:273–287.
    1. Meyer DM, Jesson MI, Li X, Elrick MM, Funckes-Shippy CL, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550 in rat adjuvant-induced arthritis. J Inflamm (Lond) 2010;7:41.
    1. Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186:4234–4343.
    1. Liew SH, Nichols KK, Klamerus KJ, Li JZ, Zhang M, Foulks GN. Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a Phase 1/2 trial. Ophthalmology. 2012;119:1328–1335.
    1. Huang JF, Yafawi R, Zhang M, McDowell M, Rittenhouse KD, Sace F, et al. Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease. Ophthalmology. 2012;119:e43–50.
    1. Murphy CJ, Bentley E, Miller PE, McIntyre K, Leatherberry G, Dubielzig R, et al. The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs. Invest Ophthalmol Vis Sci. 2011;52:3174–3180.
    1. Semba CP, Torkildsen GL, Lonsdale JD, McLaurin EB, Geffin JA, Mundorf TK, et al. A Phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye. Am J Ophthalmol. 2012;153:1050–1060.
    1. Cavet M, Harrington K, Ward K, Zhang JZ. Mapracorat, a novel selective glucocorticoid receptor agonist, inhibits hyperosmolar-induced cytokine release and MAPK pathways in human corneal epithelial cells. Mol Vis. 2010;16:1791–1800.
    1. Shafiee A, Bucolo C, Budzynski E, Ward KW, López FJ. In vivo ocular efficacy profile of mapracorat, a novel selective glucocorticoid receptor agonist, in rabbit models of ocular disease. Invest Ophthalmol Vis Sci. 2011;52:1422–1430.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe